ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

30.13

+0.09 (0.30%)

Apr 29, 2026, 12:30 PM EDT - Market open

ArriVent BioPharma Employees

ArriVent BioPharma had 77 employees as of December 31, 2025. The number of employees increased by 25 or 48.08% compared to the previous year.

Employees

77

Change (1Y)

25

Growth (1Y)

48.08%

Revenue / Employee

n/a

Profits / Employee

-$2,159,844

Market Cap

1.33B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	77	25	48.08%
Dec 31, 2024	52	12	30.00%
Dec 31, 2023	40	-	-

Related Stocks

Company Name	Employees
Iovance Biotherapeutics	975
Novavax	749
Wave Life Sciences	317
Viridian Therapeutics	252
Precigen	160
Maze Therapeutics	141
MapLight Therapeutics	133
Olema Pharmaceuticals	131

Employee Rankings

AVBP News

6 weeks ago - ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - GlobeNewsWire
7 weeks ago - ArriVent BioPharma Reports Full Year 2025 Financial Results - GlobeNewsWire
4 months ago - ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - GlobeNewsWire
6 months ago - ArriVent BioPharma Reports Third Quarter 2025 Financial Results - GlobeNewsWire
7 months ago - ArriVent Appoints Brent S. Rice as Chief Commercial Officer - GlobeNewsWire
8 months ago - Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer - GlobeNewsWire
9 months ago - ArriVent BioPharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
10 months ago - ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - GlobeNewsWire